Bullish Outlook: Pharma & Auto Stocks Poised for Growth Amid Global Challenges

Pankaj Pandey has provided a positive outlook on the Indian pharmaceutical and automotive sectors, despite ongoing global challenges like US tariffs. He specifically identified Jubilant Pharma, Piramal Pharma, and Sun Pharma as beneficiaries in the pharma space, and Maruti Suzuki, M&M, TVS, Eicher, and Bajaj Auto in the auto sector.

This analysis is significant for Indian market participants as it pinpoints specific companies and sectors that are expected to perform well, offering potential investment opportunities. The insights suggest that certain Indian industries are resilient to external pressures and possess strong internal growth drivers, which can attract FII and DII interest.

The pharmaceutical sector, particularly JUBILANTPH, PIRAMALPH, and SUNPHARMA, is expected to see positive sentiment due to limited tariff impact and domestic capex. The auto sector, including MARUTI, M&M, TVSMOTOR, EICHERMOT, and BAJAJ-AUTO, is also set for positive impact driven by robust volume growth and price hikes. This could lead to upward price movements in these specific stocks.

Traders should monitor the quarterly results of these mentioned companies for confirmation of volume growth and profitability. Keep an eye on any further policy changes regarding US tariffs and their actual impact on pharma exports. Also, track auto sales data and commodity prices, which could influence the auto sector's margins.

• •Pankaj Pandey sees limited impact on pharma growth from US tariffs.
• •Jubilant Pharma and Piramal Pharma are identified as potential beneficiaries.
• •Sun Pharma's domestic capex is considered a positive factor.
• •The auto sector shows robust volume growth and price hikes.
• •Maruti Suzuki, M&M, TVS, Eicher, and Bajaj Auto are favored in the auto sector.